For the First Time, a Cell Built From Scratch Grows and Divides
Yasemin Saplakoglu / quantamagazine - Scientists built a synthetic cell that combines more lifelike properties than ever before — proof of concept that it’s possible to bring nonliving materials to life, or something close to it, in the lab. The post For the First Time, a Cell Built From Scra…
AI Summary: Scientists have for the first time built a synthetic cell from scratch that completes a full life cycle — growing and dividing in the lab. The milestone demonstrates control over core cellular processes, opening doors for bespoke biomanufacturing and disease modelling, while reviving familiar ethical and biosafety questions. Yes, it’s breathtaking — and yes, we should probably be cautious.
Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence Over Tamoxifen and Further Reduction Is Seen When Combined with Exemestane
esmo - Findings from the SOFT and TEXT studies
AI Summary: A new analysis shows adding ovarian function suppression to tamoxifen substantially lowers recurrence in premenopausal breast cancer patients compared with tamoxifen alone, with even greater reduction when switched to exemestane. Clinicians should note the clear endocrine benefit — and patients can sigh with cautious optimism while weighing menopausal side effects.
The US is hooked on unregulated peptides. But are they effective, or even safe?
livescience - The world of peptides has exploded in wellness circles, but the benefits of injecting these gray-market molecules rest on little clinical evidence.
AI Summary: Unregulated peptide products have proliferated in the US, raising safety and efficacy concerns as federal regulators convene a contentious panel that includes proponents of these off‑label compounds. The debate highlights a market gap where hype often outpaces evidence — and where regulators must decide whether to tidy up the wild west or watch it fester.
- FDA advisory showdown: whether to rein in wellness peptides (4)
- Gray-market surge: safety, evidence gaps and booming trade (4)
FDA advisory showdown: whether to rein in wellness peptides
Gray-market surge: safety, evidence gaps and booming trade
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camelia Benlabiod, / science - Science Translational Medicine, Volume 18, Issue 856, July 2026.
AI Summary: Preclinical studies show CAR‑T cells engineered to target mutant calreticulin selectively eliminate disease‑driving clones in xenografts and human organoid models of myelofibrosis. The results reveal a potentially curative approach for a previously intractable mutation‑driven disease, though safety, on‑target effects and clinical translation remain to be rigorously tested.
CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced RCC
oncodaily - First-line treatment for advanced renal cell carcinoma has changed substantially with the use of immune checkpoint inhibitor-based regimens. Long-term follow-up is important to show whether these early survival and response […]
AI Summary: Long‑term CheckMate‑214 data comparing nivolumab plus ipilimumab against sunitinib in advanced renal cell carcinoma show sustained survival benefits for the immunotherapy combination at nine years. The follow‑up reinforces durable responses in a defined subgroup, helping clinicians refine long‑term treatment sequencing and expectations for metastatic RCC.
Anthropic Launches Claude Science to Court Pharma Ahead of IPO
Katie Adams / medcitynews - Anthropic unveiled Claude Science, an AI workbench designed to run — not just assist with — pharma research. The company is seeking to build out its customer base in the pharma sector as it deepens its healthcare push ahead of a widely anticipated IPO.The…
AI Summary: Anthropic has rolled out Claude Science to court pharmaceutical partners and stake a claim in drug discovery, signaling a pivot from conversational AI toward biology and chemistry workflows. The move accelerates competition in AI‑driven target ID and molecule design, promising speed and scale — and giving traditional drug hunters a new set of algorithms to either fear or befriend.
Evernorth unveils new AI-powered specialty pharmacy program, Pharmacy Forward
fiercehealthcare - Evernorth has unveiled a new specialty pharmacy program that leans on AI to support a better experience for patients with complex conditions.
AI Summary: Evernorth announced a $100 million investment to roll out an AI‑driven specialty pharmacy program designed to streamline specialty drug management, improve medication access, and optimize operations. The program blends automation and data analytics to cut friction in high‑cost therapies — promising efficiency gains if the tech behaves, which is always the question.
EMERALD-3 at ESMO GI 2026: Tremelimumab Plus Durvalumab With or Without Lenvatinib Plus TACE in Embolisation-Eligible HCC
oncodaily - In the Proffered Paper session, Joseph P. Erinjeri from New York, United States, presented updated tumour response analyses from the phase III EMERALD-3 study. The abstract, titled “Tumour response analyses […]
AI Summary: EMERALD‑3, presented at ESMO GI 2026, evaluates tremelimumab plus durvalumab with or without lenvatinib and TACE in embolisation‑eligible hepatocellular carcinoma. The trial probes whether adding systemic immunotherapy to locoregional strategies improves outcomes for patients traditionally steered toward embolisation, potentially redefining combination approaches in intermediate‑stage HCC.
Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine
Frank Vinluan / medcitynews - FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a common complication of the allogeneic stem cell transplants that are a stan…
AI Summary: Orca Bio’s off‑the‑shelf allogeneic cell therapy received FDA approval, marking a milestone for engineered living medicines. Regulators cleared the product after pivotal efficacy and manufacturing data, offering broader access to cellular therapy but spotlighting cost, supply logistics and the need for robust post‑market safety surveillance.
'Polypill' for heart failure cuts hospitalizations and ER visits by 60% in trial
medicalxpress - A "polypill" combining three medications recommended to treat heart failure into a single daily dose proved far more effective for patients than taking the drugs separately, a randomized clinical trial led by UT Southwestern Medical Center researchers sho…
AI Summary: The POLY‑HF randomized trial found that a fixed‑dose 'polypill' for heart failure with reduced ejection fraction cut hospitalizations and emergency visits by roughly 60%, improving adherence and standardizing therapy. Results suggest a pragmatic, low‑complexity intervention could deliver substantial health‑system benefits if adopted broadly and monitored for implementation challenges.
Bacteria-killing viruses redirect vaccine immunity to destroy cancer
newscientist - Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from vaccines
AI Summary: Researchers show bacteriophages can redirect existing vaccine‑induced immunity to attack cancer cells, effectively hijacking antiviral immune memory to target tumours. This clever preclinical strategy repurposes phages as delivery vehicles and immunomodulators, opening a potential new class of off‑the‑shelf immunotherapies that could complement or bypass current T‑cell approaches — if it survives the usual valley of translation.
Cancer drug shortage renews calls for federal action
medicalxpress - Cancer doctors across the United States are running short of essential generic chemotherapy drugs, and some fear the squeeze could force widespread rationing, The New York Times reported.
AI Summary: Hospitals and oncology clinics are facing critical shortages of key chemotherapy agents, forcing clinicians to consider rationing or alternative regimens. The supply squeeze has reignited demands for federal intervention, supply‑chain fixes, and clearer contingency plans to protect patients who can’t exactly wait for bureaucratic miracles.
A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management
Sandeep Palakodeti / medcitynews - For seniors, the change in policy will dramatically expand access to a revolutionary medication. But there are also significant risks.The post A Bridge to Nowhere? Medicare’s GLP-1 Coverage Expansion Requires A More Holistic Approach To Weight Management …
AI Summary: Medicare’s planned GLP‑1 coverage “bridge” has kicked off a scramble: policy analysts warn a narrow drug‑centric approach won’t fix weight management, while major retailers are rolling out programs and partnerships to plug access gaps. Expect patchwork solutions, eager pharmacies, and a chorus asking for a more holistic long‑term plan.
- Clinical risks and long-term effectiveness debate (5)
- Medicare Bridge rollout, eligibility and cost questions (5)
- Online prescribing, oversight and soaring GLP‑1 use (4)
- Retailers, pharmacies and manufacturers rush to plug access gaps (4)
- All Other Stories
Clinical risks and long-term effectiveness debate
Medicare Bridge rollout, eligibility and cost questions
Online prescribing, oversight and soaring GLP‑1 use
Retailers, pharmacies and manufacturers rush to plug access gaps
All Other Stories
Updated Long-Term Follow-Up From the Phase 1b BOT+BAL Study at ESMO GI 2026 – Agenus
oncodaily - Agenus shared a post on LinkedIn: “At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal […]
AI Summary: Updated follow‑up data presented for botensilimab plus balstilimab reveal meaningful and durable activity in microsatellite‑stable metastatic colorectal cancer, with especially encouraging outcomes in patients lacking active liver metastases. The Agenus combination, showcased at a major gastrointestinal oncology meeting, renews interest in immune strategies for historically refractory MSS disease.
- Agenus releases Phase 1b three-year BOT+BAL survival data (2)
- Clinical and community reaction: experts weigh in on BOT+BAL (3)
- ESMO GI: BOT+BAL benefits in patients without active liver metastases (3)
- All Other Stories
Agenus releases Phase 1b three-year BOT+BAL survival data
Clinical and community reaction: experts weigh in on BOT+BAL
ESMO GI: BOT+BAL benefits in patients without active liver metastases
All Other Stories
RWJBarnabas Health, Rutgers open $225M cancer center
Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …
AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.
- ASCO shockwave: Daraxonrasib survival curve draws standing ovation (3)
- Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing (4)
- Conference context: RAS momentum and expert reflections (5)
- Rapid off‑trial rollout and early patient access (4)
- All Other Stories
ASCO shockwave: Daraxonrasib survival curve draws standing ovation
Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing
Conference context: RAS momentum and expert reflections
Rapid off‑trial rollout and early patient access
All Other Stories
FDA Approves Gilead’s Trodelvy, Alone and With Merck’s Keytruda, in First-Line Metastatic TNBC
oncodaily - Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients. The U.S. Food and […]
AI Summary: The FDA approved sacituzumab govitecan (Trodelvy) as both monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of metastatic triple‑negative breast cancer, expanding options for a hard-to-treat population. Regulators cited clinical benefit in appropriate patients, reshaping treatment sequencing and payer discussions.
A Ban Won’t Stop Abortion Pill Access, Telehealth Providers Say
Kate Wells / kffhealthnews - As a federal court mulls a case that could result in significant restrictions on a pill used in most abortions, providers say they have alternatives to preserve access even in states with bans in place.
AI Summary: Providers and telehealth advocates warn that banning access won’t stop patients from obtaining abortion pills online. Telemedicine and pharmacy workarounds continue to provide routes for care, underscoring limits of state bans and foreshadowing prolonged legal and practical battles over remote prescribing, cross‑border services, and patient privacy.
As PBM industry shifts, LucyRx and Abarca Health merge to build scale
fiercehealthcare - Amid significant shifts in the pharmacy benefit management industry, LucyRx and Abarca Health have revealed plans to merge to build the scale necessary to compete in this changing landscape.
AI Summary: Two independent pharmacy benefit managers, LucyRx and Abarca Health, announced a combination to build scale amid industry consolidation. The deal aims to bolster negotiating leverage, broaden client reach and offer an alternative to dominant PBMs—because apparently one disruptor wasn’t enough to disrupt the disruptors.
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
esmo -
AI Summary: Regulators have approved datopotamab deruxtecan for patients with unresectable or metastatic triple‑negative breast cancer, offering a new targeted option where few exist. The decision follows trial evidence of meaningful anti‑tumor activity and expands the treatment toolkit for aggressive TNBC subtypes, with clinicians weighing sequencing and toxicity management.
Ashok Sebastian Komaranchath: Delighted to Speak at the 5th International Oncology Forum on 20–21 June 2026
oncodaily - Ashok Sebastian Komaranchath, Consultant Medical Oncology and Clinical Lead for Oncology Services at Burjeel Cancer Institute, Oman, shared on LinkedIn: “I was delighted to speak at the 5th International Oncology Forum […]
AI Summary: The FDA (and HHS) launched Operation TrialBlazer, an initiative to accelerate and modernize clinical development by streamlining trial design, data sharing and regulatory pathways. The program aims to reclaim trial competitiveness and reduce time‑to‑market, promising faster patient access — if stakeholders can agree on what “modernize” actually means.